1987
DOI: 10.1097/00004714-198702000-00028
|View full text |Cite
|
Sign up to set email alerts
|

Hepatotoxicity Following Treatment with Maprotiline

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

1988
1988
2016
2016

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 7 publications
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…In a review, Klerman and Cole [104] reported that the incidence of jaundice in patients treated with imipramine is 0.5-1%. Isolated cases of jaundice have been re ported [105][106][107], In another series of 500 patients, no incidence of jaundice was noted [108], Acute hepatitis has been reported with the administration of amitriptyline [109][110][111][112], imipramine [96,[113][114][115], desipramine [116], maprotiline [117], and phenelzine [102], The overall incidence of hepatotoxicity of phenelzine has been reported to be approxi mately 1%. Patients with cirrhosis are likely to exhibit marked sensitivity to tranylcy promine and other MAOIs.…”
Section: Tricyclicsmentioning
confidence: 99%
“…In a review, Klerman and Cole [104] reported that the incidence of jaundice in patients treated with imipramine is 0.5-1%. Isolated cases of jaundice have been re ported [105][106][107], In another series of 500 patients, no incidence of jaundice was noted [108], Acute hepatitis has been reported with the administration of amitriptyline [109][110][111][112], imipramine [96,[113][114][115], desipramine [116], maprotiline [117], and phenelzine [102], The overall incidence of hepatotoxicity of phenelzine has been reported to be approxi mately 1%. Patients with cirrhosis are likely to exhibit marked sensitivity to tranylcy promine and other MAOIs.…”
Section: Tricyclicsmentioning
confidence: 99%